BRPI0407149A - Formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais - Google Patents

Formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Info

Publication number
BRPI0407149A
BRPI0407149A BR0407149-2A BRPI0407149A BRPI0407149A BR PI0407149 A BRPI0407149 A BR PI0407149A BR PI0407149 A BRPI0407149 A BR PI0407149A BR PI0407149 A BRPI0407149 A BR PI0407149A
Authority
BR
Brazil
Prior art keywords
rifaximin
production
polymorphic forms
processes
medicinal preparations
Prior art date
Application number
BR0407149-2A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of BRPI0407149A publication Critical patent/BRPI0407149A/pt
Publication of BRPI0407149A8 publication Critical patent/BRPI0407149A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMAS POLIMóRFICAS DE RIFAXIMIN, PROCESSOS PARA SUA PRODUçãO E SEU USO EM PREPARAçõES MEDICINAIS". A presente invenção refere-se a formas polimórficas cristalinas de rifaximin (INN), referidas como rifaximin alfa e rifaximin beta, e a uma forma pobremente cristalina referida como rifaximin gama, úteis na produção de medicamentos contendo rifaximin para o uso oral e tópico e obtidas por meio de um processo de cristalização realizado por dissolução quente de rifaximin bruto em álcool etílico e causando a cristalização do produto pela adição de água em uma temperatura fixada e por um período de tempo fixado, seguido por secagem sob condições controladas até atingir um preciso teor de água no produto final, são os objetos da invenção.
BRPI0407149A 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais BRPI0407149A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
PCT/EP2004/012490 WO2005044823A2 (en) 2003-11-07 2004-11-04 Polymorphous forms of rifaximin as antibiotics

Publications (2)

Publication Number Publication Date
BRPI0407149A true BRPI0407149A (pt) 2006-02-07
BRPI0407149A8 BRPI0407149A8 (pt) 2019-01-15

Family

ID=33187382

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0402382-0A BRPI0402382A (pt) 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais
BRPI0407149A BRPI0407149A8 (pt) 2003-11-07 2004-11-04 formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0402382-0A BRPI0402382A (pt) 2003-11-07 2004-03-19 Formas polimórficas de rifaximina, processos para a produção das mesmas e uso das mesmas em preparações medicinais

Country Status (37)

Country Link
US (5) US7045620B2 (pt)
EP (6) EP1676847B1 (pt)
JP (5) JP2005139161A (pt)
KR (4) KR20050043589A (pt)
CN (4) CN1613858A (pt)
AR (3) AR043547A1 (pt)
AT (3) ATE361927T1 (pt)
AU (2) AU2004200964A1 (pt)
BR (2) BRPI0402382A (pt)
CA (2) CA2460384A1 (pt)
CL (1) CL2004000498A1 (pt)
CO (1) CO5560083A1 (pt)
CY (3) CY1108017T1 (pt)
DE (4) DE602004006367C5 (pt)
DK (3) DK1676847T3 (pt)
ES (3) ES2244364T3 (pt)
HR (2) HRP20040265A2 (pt)
IL (2) IL160798A0 (pt)
IT (1) ITMI20032144A1 (pt)
JO (1) JO2470B1 (pt)
MA (1) MA27069A1 (pt)
MD (1) MD3653G8 (pt)
ME (1) ME00424B (pt)
MX (2) MXPA04002353A (pt)
NO (1) NO334950B1 (pt)
NZ (1) NZ531622A (pt)
PL (3) PL1676847T3 (pt)
PT (3) PT1557421E (pt)
RS (4) RS54571B1 (pt)
RU (1) RU2270200C2 (pt)
SI (3) SI1557421T1 (pt)
TN (2) TNSN04044A1 (pt)
TW (1) TWI285107B (pt)
UA (1) UA86384C2 (pt)
WO (1) WO2005044823A2 (pt)
YU (1) YU24804A (pt)
ZA (1) ZA200401948B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
MX2009001342A (es) 2006-08-02 2009-08-31 Salix Pharmaceuticals Inc Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) * 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8067429B2 (en) * 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
PT2252148T (pt) * 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
HRP20140939T1 (hr) 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
KR20190099100A (ko) 2009-06-02 2019-08-23 샐릭스 파마슈티컬스 리미티드 간성 뇌병증의 치료방법
NZ598671A (en) 2009-09-13 2014-02-28 Salix Pharmaceuticals Ltd Methods for treating irritable bowel syndrome (ibs)
RU2012121599A (ru) * 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
WO2012109605A2 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
US20160047819A1 (en) 2013-03-15 2016-02-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
HUE040253T2 (hu) 2016-03-24 2019-02-28 Sandoz Ag Rifaximin alfa&deltát tartalmazó gyógyászati készítmény
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (en) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
US20050272754A1 (en) 2005-12-08
ES2320161T3 (es) 2009-05-19
EP1557421A1 (en) 2005-07-27
CA2538546A1 (en) 2005-05-19
HK1073657A1 (en) 2005-10-14
US20050101598A1 (en) 2005-05-12
EP1557421B1 (en) 2007-05-09
ITMI20032144A1 (it) 2005-05-08
HK1092151A1 (en) 2007-02-02
ES2244364T1 (es) 2005-12-16
US7915275B2 (en) 2011-03-29
JP5199576B2 (ja) 2013-05-15
JP2011057698A (ja) 2011-03-24
EP1676848B1 (en) 2009-01-28
NZ531622A (en) 2004-10-29
PT1557421E (pt) 2007-07-31
RU2270200C2 (ru) 2006-02-20
AR081991A2 (es) 2012-10-31
AR043547A1 (es) 2005-08-03
EP1676848A1 (en) 2006-07-05
WO2005044823A2 (en) 2005-05-19
PL1676847T3 (pl) 2009-07-31
RS20060168A (sr) 2008-09-29
DE602004006367D1 (de) 2007-06-21
JP2011046738A (ja) 2011-03-10
JP2007509904A (ja) 2007-04-19
IL160798A0 (en) 2004-08-31
CA2538546C (en) 2011-04-19
DK1676847T3 (da) 2009-05-11
PL1557421T3 (pl) 2007-08-31
MD3653F2 (en) 2008-07-31
KR100883216B1 (ko) 2009-02-13
AU2004287601A1 (en) 2005-05-19
EP2210893A1 (en) 2010-07-28
CA2460384A1 (en) 2005-05-07
CO5560083A1 (es) 2005-09-30
DK1676848T3 (da) 2009-05-11
ATE421965T1 (de) 2009-02-15
DE602004019296D1 (de) 2009-03-19
DE04005541T1 (de) 2005-12-29
CL2004000498A1 (es) 2005-03-11
MA27069A1 (fr) 2004-12-20
CY1108017T1 (el) 2013-09-04
YU24804A (sh) 2006-08-17
ME00424B (me) 2011-10-10
CY1108964T1 (el) 2014-07-02
AR081992A2 (es) 2012-10-31
CN1886408B (zh) 2010-06-09
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
KR20050043589A (ko) 2005-05-11
EP1682556A2 (en) 2006-07-26
JP2014177500A (ja) 2014-09-25
RS20150292A1 (sr) 2015-10-30
HRP20060093A2 (en) 2006-05-31
DE602004019298D1 (de) 2009-03-19
PT1676848E (pt) 2009-04-09
IL174271A (en) 2010-12-30
ATE421966T1 (de) 2009-02-15
CN101260114B (zh) 2012-11-28
RU2004108953A (ru) 2005-10-27
PT1676847E (pt) 2009-04-09
US8404704B2 (en) 2013-03-26
US20080132530A1 (en) 2008-06-05
US20110160449A1 (en) 2011-06-30
TWI285107B (en) 2007-08-11
KR20070113327A (ko) 2007-11-28
RS54569B1 (sr) 2016-06-30
CY1108909T1 (el) 2014-07-02
RS54571B1 (sr) 2016-06-30
AU2004287601B8 (en) 2009-03-05
RS20150291A1 (sr) 2015-10-30
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
ZA200401948B (en) 2004-04-29
KR100855084B1 (ko) 2008-08-29
CN1886408A (zh) 2006-12-27
KR100867751B1 (ko) 2008-11-10
AU2004200964A1 (en) 2005-05-26
KR20060110737A (ko) 2006-10-25
BRPI0402382A (pt) 2005-06-28
DE602004006367C5 (de) 2019-04-04
TW200515913A (en) 2005-05-16
BRPI0407149A8 (pt) 2019-01-15
TNSN06069A1 (en) 2007-10-03
NO20061110L (no) 2006-04-19
US8173801B2 (en) 2012-05-08
DE602004006367T2 (de) 2007-09-06
MXPA04002353A (es) 2005-05-11
SI1557421T1 (sl) 2007-08-31
DK1557421T3 (da) 2007-09-17
AU2004287601B2 (en) 2009-02-26
CN101260114A (zh) 2008-09-10
ES2320160T4 (es) 2011-03-09
HRP20060093B1 (hr) 2015-12-18
JP5635376B2 (ja) 2014-12-03
CN101260115A (zh) 2008-09-10
RS54568B1 (sr) 2016-06-30
EP1676847A1 (en) 2006-07-05
IL174271A0 (en) 2006-08-01
CN1613858A (zh) 2005-05-11
US7045620B2 (en) 2006-05-16
MD3653G8 (ro) 2016-08-31
TNSN04044A1 (en) 2006-06-01
US20120059023A1 (en) 2012-03-08
UA86384C2 (uk) 2009-04-27
JP2005139161A (ja) 2005-06-02
SI1676848T1 (sl) 2009-06-30
MD20060080A (en) 2006-11-30
ATE361927T1 (de) 2007-06-15
MXPA06002644A (es) 2006-06-06
ES2244364T3 (es) 2007-12-01
HK1092150A1 (en) 2007-02-02
JO2470B1 (en) 2009-01-20
CN101260115B (zh) 2011-11-23
SI1676847T1 (sl) 2009-06-30
NO334950B1 (no) 2014-08-04
KR20070113326A (ko) 2007-11-28
EP1676847B1 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
BRPI0407149A8 (pt) formas polimórficas de rifaximin, processos para sua produção e seu uso em preparações medicinais
BRPI0608073A2 (pt) formas polimorfas de rifaximina, processos para sua produção e uso das mesmas em composições medicinais
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
CR8975A (es) Proceso para la produccion de derivados de amina opticamente activos
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
ATE509900T1 (de) Kristallisation von polyolzusammensetzungen, kristallines polyolzusammensetzungsprodukt und dessen verwendung
Tamura et al. A novel method for sulfilimines and sulfoximines
BRPI0715853A8 (pt) Uso de polióis contendo pelo menos dois grupos hidróxi para estabilizar formas polimorfas da rifaximina, rifaximina beta, suas preparações medicinais, seus microgrânulos e seu processo de preparação
BRPI0408150A (pt) composto, seu uso e processo para preparação do mesmo, métodos para tratamento ou profilaxia de cáncer e para produção de um efeito inibidor do ciclo celular (anti - proliferação celular) em um animal de sangue quente e composição farmacêutica
BR112019002432A2 (pt) cristalização de glicosídeos de esteviol
AR046229A1 (es) Procesos para la preparacion de cefalosporina 3-(2-vinilo sustituido) altamente pura
US11925654B2 (en) Esters of 2-deoxy-monosaccharides with anti proliferative activity
BRPI0810609A2 (pt) Métodos para a preparação de derivados de n-isobutil-n-(2-hidróxi-a-amino-4-fenilbutil)-p-nitrobe nzenossulfonilamida
BR0015877A (pt) Polimorfo v de torasemida
BRPI0719205B1 (pt) pleuromutilinas, seus intermediários, seu sal de adição de ácido e seu processo para preparação, e composição farmacêutica
AR024226A1 (es) Vancorresmicina, un proceso para su produccion, un cultivo de microorganismos para su preparacion, composicion farmaceutica que la contiene
BRPI0509028A (pt) processo para produção de derivados de c-glicosìdeo de flavona
NO20080940L (no) Ikke-steroide forbindelser anvendbare som glukokortikoide reseptor modulatorer
BR0010637A (pt) Composto, processo para produzir um composto, composição farmacêutica ou veterinária, inibidor de metaloproteinase, e, medicamento profilático e/ou terapêutico para doenças e/ou distúrbios associados com a degradação de tecido
AR047061A1 (es) Sintesis de un polimorfo de clorhidrato hidratado de 4-amino-5-cloro-2-metoxi-n-(1-azabiciclo[3.3.1]non-4-il)benzamida
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
TH2101003549A (th) รูปแบบผลึกของสารยับยั้ง par4
AR058282A1 (es) Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
ES2112597T3 (es) Nuevos derivados de 17-(3-imino-2-alquil-propenil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
BRPI0807799B8 (pt) derivados de 2-piperazin-1-il-3h-imidazo[4,5-b]piridina, composição farmacêutica que os compreende, seu processo de preparação e uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL